Olink Holding AB is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions. The company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.
Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC acted as lead book-running managers for the offering. SVB Leerink LLC acted as a joint book-running manager. BTIG, LLC acted as co-manager.
Baker McKenzie acted as legal advisor to the minority selling shareholders with a team consisting of Henric Roth, Ian Gulam and Linnea Back in Stockholm, Adam Farlow and Megan Schellinger in London, as well as additional lawyers from Baker McKenzie offices in the US.